As of 2026-09-02 10:39 UTC.Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
The survey indicated that 80 percent of respondents believed food recalls were effective in protecting public health and safety in 2026, down from 85 percent in 2025. [1][4][5]
Optiscan Imaging Ltd, a company listed on the Australian Securities Exchange under the ticker ASX:OIL, has initiated a new clinical study. [2] UBS initiated coverage of Getinge with a Neutral rating and a price target of 255 Swedish crowns, stating that the medical equipment maker's shares are priced as if quality issues are fully resolved. [3] Optiscan Imaging Ltd has partnered with the Mayo Clinic to conduct this clinical evaluation. [6]
The results of this study are intended to support the company's future submissions to the US Food and Drug Administration (FDA). [7] The study is based in the United States and focuses on imaging for head and neck cancer. [8] Remediation costs have amounted to almost 20% of the company's cumulative free cash flow since 2015, according to UBS. [9]
UBS classified Getinge's portfolio into three buckets - Growth Accelerators, Steady Compounders, and Growth Detractors - with Growth Accelerators expected to rise from under 30% of sales in 2025 to almost 35% by 2030. [10] UBS forecasts Getinge to deliver a 5% revenue and 12% earnings-per-share compound annual growth rate for 2026-2030, driven by a portfolio mix shift toward higher-growth product categories. [11] 59 percent of respondents said they had discarded recalled food even when their state or region was not affected, compared with 57 percent in 2025. [12]La encuesta indicó que el 80 por ciento de los encuestados consideró que los retiros de alimentos eran efectivos para proteger la salud y la seguridad pública en 2026, frente al 85 por ciento en 2025. [1][4][5]
Optiscan Imaging Ltd, una empresa que cotiza en la Bolsa de Valores de Australia bajo el ticker ASX:OIL, ha iniciado un nuevo estudio clínico. [2] UBS inició la cobertura de Getinge con una calificación Neutral y un precio objetivo de 255 coronas suecas, afirmando que las acciones del fabricante de equipos médicos están valoradas como si los problemas de calidad estuvieran completamente resueltos. [3] Optiscan Imaging Ltd se ha asociado con la Clínica Mayo para llevar a cabo esta evaluación clínica. [6]
Se espera que los resultados de este estudio respalden las futuras presentaciones de la empresa ante la Administración de Alimentos y Medicamentos de EE. UU. (FDA). [7] El estudio tiene su sede en Estados Unidos y se centra en imágenes para el cáncer de cabeza y cuello. [8] Los costos de remediación han ascendido a casi el 20% del flujo de caja libre acumulado de la empresa desde 2015, según UBS. [9]
UBS clasificó la cartera de Getinge en tres categorías: Aceleradores de Crecimiento, Compuestos Estables y Detractores de Crecimiento, y se espera que los Aceleradores de Crecimiento aumenten de menos del 30% de las ventas en 2025 a casi el 35% para 2030. [10] UBS pronostica que Getinge logrará una tasa de crecimiento anual compuesta del 5% en ingresos y del 12% en ganancias por acción para 2026-2030, impulsada por un cambio en la mezcla de cartera hacia categorías de productos de mayor crecimiento. [11] El 59 por ciento de los encuestados dijo que había desechado alimentos retirados incluso cuando su estado o región no se veía afectado, en comparación con el 57 por ciento en 2025. [12]
Proof12 sources · 3 publishers
What this stands on
A survey commissioned by GS1 US found that 94 percent of U.S. adults were concerned about the frequency of food recalls in 2026, up from 93 percent in 2025. · food-safety.com
Optiscan Imaging Ltd, a company listed on the Australian Securities Exchange under the ticker ASX:OIL, has initiated a new clinical study. · South Florida Reporter
UBS initiated coverage of Getinge with a Neutral rating and a price target of 255 Swedish crowns, stating that the medical equipment maker's shares are priced as if quality issues are fully resolved. · Investing.com
67 percent of survey respondents said they had avoided an entire food product category following a recall, up from 60 percent in 2025. · food-safety.com
The survey indicated that 80 percent of respondents believed food recalls were effective in protecting public health and safety in 2026, down from 85 percent in 2025. · food-safety.com
Optiscan Imaging Ltd has partnered with the Mayo Clinic to conduct this clinical evaluation. · South Florida Reporter
The results of this study are intended to support the company's future submissions to the US Food and Drug Administration (FDA). · South Florida Reporter
The study is based in the United States and focuses on imaging for head and neck cancer. · South Florida Reporter
Remediation costs have amounted to almost 20% of the company's cumulative free cash flow since 2015, according to UBS. · Investing.com
UBS classified Getinge's portfolio into three buckets - Growth Accelerators, Steady Compounders, and Growth Detractors - with Growth Accelerators expected to rise from under 30% of sales in 2025 to almost 35% by 2030. · Investing.com
UBS forecasts Getinge to deliver a 5% revenue and 12% earnings-per-share compound annual growth rate for 2026-2030, driven by a portfolio mix shift toward higher-growth product categories. · Investing.com
59 percent of respondents said they had discarded recalled food even when their state or region was not affected, compared with 57 percent in 2025. · food-safety.com
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Wednesday, September 2, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world3 publishers reported the events across 3 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.